Literature DB >> 19805306

aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6.

Hitoshi Ishiguro1, Kazunori Akimoto, Yoji Nagashima, Yasuyuki Kojima, Takeshi Sasaki, Yukari Ishiguro-Imagawa, Noboru Nakaigawa, Shigeo Ohno, Yoshinobu Kubota, Hiroji Uemura.   

Abstract

Understanding the mechanism by which hormone refractory prostate cancer (HRPC) develops remains a major issue. Alterations in HRPC include androgen receptor (AR) changes. In addition, the AR is activated by cytokines such as interleukin-6 (IL-6). Atypical protein kinase C (aPKClambda/iota) has been implicated in the progression of several cancers. Herein, we provide evidence that aPKClambda/iota expression correlates with prostate cancer recurrence. Experiments in vitro and in vivo revealed aPKClambda/iota to be involved in prostate cancer cell growth through secretion of IL-6. Further, aPKClambda/iota activates transcription of the IL-6 gene through NFkappaB and AP-1. We conclude that aPKClambda/iota promotes the growth of hormone independent prostate cancer cells by stimulating IL-6 production in an autocrine manner. Our findings not only explain the link between aPKClambda/iota and IL-6, implicated in the progression a variety of cancers, but also establish a molecular change involved in the development of HRPC. Further, aPKClambda/iota expression might be a biomarker for prostate cancer progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19805306      PMCID: PMC2752573          DOI: 10.1073/pnas.0907044106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  RhoA-dependent murine prostate cancer cell proliferation and apoptosis: role of protein kinase Czeta.

Authors:  Paramita M Ghosh; Roble Bedolla; Margharita Mikhailova; Jeffrey I Kreisberg
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

Review 2.  Intercellular junctions and cellular polarity: the PAR-aPKC complex, a conserved core cassette playing fundamental roles in cell polarity.

Authors:  S Ohno
Journal:  Curr Opin Cell Biol       Date:  2001-10       Impact factor: 8.382

3.  Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway .

Authors:  W Lou; Z Ni; K Dyer; D J Tweardy; A C Gao
Journal:  Prostate       Date:  2000-02-15       Impact factor: 4.104

4.  Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity.

Authors:  Roderick P Regala; Capella Weems; Lee Jamieson; John A Copland; E Aubrey Thompson; Alan P Fields
Journal:  J Biol Chem       Date:  2005-07-01       Impact factor: 5.157

5.  Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue.

Authors:  A Hobisch; H Rogatsch; A Hittmair; D Fuchs; G Bartsch; H Klocker; G Bartsch; Z Culig
Journal:  J Pathol       Date:  2000-07       Impact factor: 7.996

6.  Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression.

Authors:  D L Lin; M C Whitney; Z Yao; E T Keller
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

7.  Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis.

Authors:  S F Shariat; B Andrews; M W Kattan; J Kim; T M Wheeler; K M Slawin
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

8.  Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.

Authors:  P C Smith; E T Keller
Journal:  Prostate       Date:  2001-06-15       Impact factor: 4.104

9.  NF-kappaB/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival.

Authors:  Y Lu; L Jamieson; A R Brasier; A P Fields
Journal:  Oncogene       Date:  2001-08-09       Impact factor: 9.867

10.  Serum interleukin 6 as a prognostic factor in patients with prostate cancer.

Authors:  J Nakashima; M Tachibana; Y Horiguchi; M Oya; T Ohigashi; H Asakura; M Murai
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

View more
  35 in total

Review 1.  Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Authors:  Nagalakshmi Nadiminty; Allen C Gao
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

2.  Growth hormone abolishes beneficial effects of calorie restriction in long-lived Ames dwarf mice.

Authors:  Adam Gesing; Khalid A Al-Regaiey; Andrzej Bartke; Michal M Masternak
Journal:  Exp Gerontol       Date:  2014-08-21       Impact factor: 4.032

3.  JunD-mediated repression of GADD45α and γ regulates escape from cell death in prostate cancer.

Authors:  Luiz Fernando Zerbini; Jaíra Ferreira de Vasconcellos; Akos Czibere; Yihong Wang; Juliano D Paccez; Xuesong Gu; Jin-Rong Zhou; Towia A Libermann
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

Review 4.  Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-07-14       Impact factor: 3.647

Review 5.  The Dual Roles of the Atypical Protein Kinase Cs in Cancer.

Authors:  Miguel Reina-Campos; Maria T Diaz-Meco; Jorge Moscat
Journal:  Cancer Cell       Date:  2019-08-29       Impact factor: 31.743

Review 6.  Protein kinase C and cancer: what we know and what we do not.

Authors:  R Garg; L G Benedetti; M B Abera; H Wang; M Abba; M G Kazanietz
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

7.  PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.

Authors:  A Paul; S Gunewardena; S R Stecklein; B Saha; N Parelkar; M Danley; G Rajendran; P Home; S Ray; I Jokar; G A Vielhauer; R A Jensen; O Tawfik; S Paul
Journal:  Cell Death Differ       Date:  2014-05-02       Impact factor: 15.828

8.  miR-217-5p induces apoptosis by directly targeting PRKCI, BAG3, ITGAV and MAPK1 in colorectal cancer cells.

Authors:  Marion Flum; Michael Kleemann; Helga Schneider; Benjamin Weis; Simon Fischer; René Handrick; Kerstin Otte
Journal:  J Cell Commun Signal       Date:  2017-09-14       Impact factor: 5.782

9.  Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?

Authors:  Andrew Jarnicki; Tracy Putoczki; Matthias Ernst
Journal:  Cell Div       Date:  2010-05-17       Impact factor: 5.130

10.  New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.

Authors:  Soo Ok Lee; Zhifang Ma; Chiuan-Ren Yeh; Jie Luo; Tzu-Hua Lin; Kuo-Pao Lai; Shinichi Yamashita; Liang Liang; Jing Tian; Lei Li; Qi Jiang; Chiung-Kuei Huang; Yuanjie Niu; Shuyuan Yeh; Chawnshang Chang
Journal:  J Mol Cell Biol       Date:  2012-07-24       Impact factor: 6.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.